- CYBN partners with pioneer company focused on exploring, quantifying the human mind
- Innovative Flow technology adds exciting dimension to Cybin’s commitment to develop breakthrough treatments for mental health disorders
- Innovative technology opens new frontier in psychedelic therapeutics
Cybin (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is partnering with neurotech pioneer HI, LLC dba Kernel to quantify brain activity in real time during psychedelic experiences (https://ibn.fm/3AG5G). CYBN plans to do this by leveraging Kernel Flow, Kernel’s breakthrough technology, for its upcoming clinical work.
“Access to Kernel’s innovative Flow technology adds another exciting dimension to the investigative work that Cybin is doing to develop breakthrough treatments for mental health disorders such as depression and addiction,” said Cybin CEO Doug Drysdale. “Currently, clinical investigators rely on limited subjective information from patients. The ability to collect quantitative data from our sponsored drug-development programs is potentially game changing in terms of our ability to measure where psychedelics work in the brain in real time, and how we ultimately design our future therapeutics.
“We are delighted to partner with Kernel to study the utility of Flow in sponsored clinical settings,” he continued. “This new cornerstone component of our sponsored clinical programs follows a record-setting capital raise, listing on the NEO Exchange and the acquisition of Adelia Therapeutics Inc., which added significant scientific capabilities, novel molecules, delivery mechanisms and intellectual property.”
In announcing the agreement, Cybin noted that the absence of the data that this partnership may provide has been a limitation in the progression of new molecules targeting neurological disorders. “Kernel’s technology opens new frontier in psychedelic therapeutics by acquiring longitudinal brain activity before, during and after a psychedelic experience, enabling quantification of what was previously subjective self-reporting,” said the company, noting that the Kernel technology is unique among brain-scanning technologies and is the first commercially scalable time-domain functional near-infrared spectroscopy system.
Based in Los Angeles, Kernel is comprised of ia team of neuroscientists, physicists, engineers, programmers, and experiment and operations experts focused on exploring and quantifying the human mind. The Kernel Flow is a head-worn, scalable, noninvasive neuroimaging system that leverages time-domain functional near-infrared spectroscopy, widely recognized as a gold standard optical method for detecting hemodynamics of the cerebral cortex.
Compared to traditional near-infrared spectroscopy devices, time-domain systems obtain richer brain signals by applying light in short pulses and precisely capturing the arrival time distribution of scattered photons from each pulse. Cybin plans to use Flow measurements as analogues of local neural activity during psychedelic experiences; the company anticipates that the quantitative measurements provided by Flow could enhance the development, delivery and scaling of its psychedelic therapeutics.
As part of the agreement, Cybin plans to take delivery of Flow in Q2 2021 and will then undertake sponsored studies in a range of clinical conditions. The company will use information, data and insights collected by Flow technology in the design of future clinical studies.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN